{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=16", "query": { "condition": "Cancer of the Stomach", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 951, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T22:45:22.299Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07631000", "title": "A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal-junction Cancer" ], "interventions": [ { "name": "Cadonilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-05-27", "completion_date": "2029-05-27", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07631000" }, { "nct_id": "NCT00816777", "title": "Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Metastatic Colo-rectal Cancer" ], "interventions": [ { "name": "Chemoembolization with irinotecan Bead", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Generic Devices Consulting, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 3, "location_summary": "Aurora, Colorado • Chicago, Illinois • Burlington, Massachusetts", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00816777" }, { "nct_id": "NCT00725712", "title": "Study of GSK1363089 in Metastatic Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Gastrointestinal Tract" ], "interventions": [ { "name": "GSK1363089 (formerly XL880)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2007-03-31", "completion_date": "2009-11-30", "has_results": true, "last_update_posted_date": "2017-08-24", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725712" }, { "nct_id": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Urothelial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Gastric Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Microsatellite Instability", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "N-803 + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Nivolumab", "type": "DRUG" }, { "name": "N-803 + Atezolizumab", "type": "DRUG" }, { "name": "N-803 + Avelumab", "type": "DRUG" }, { "name": "N-803 + Durvalumab", "type": "DRUG" }, { "name": "N-803 + Pembrolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Nivolumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Atezolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Avelumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Durvalumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-12-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228667" }, { "nct_id": "NCT00003172", "title": "Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-12", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 24, "location_summary": "Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003172" }, { "nct_id": "NCT03551951", "title": "Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Pancreatic Cancer", "Hepatocellular Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "Test for circulating tumor cells, DNA alterations", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Missouri-Columbia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2016-07-01", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 1, "location_summary": "Columbia, Missouri", "locations": [ { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03551951" }, { "nct_id": "NCT05041153", "title": "Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Gastric Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-02-14", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05041153" }, { "nct_id": "NCT00264472", "title": "A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "ADH300004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adherex Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-12-15", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00264472" }, { "nct_id": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Tract Malignancies" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-06-10", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329766" }, { "nct_id": "NCT02102022", "title": "Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Gastrointestinal (GI) Malignancies", "Hepatocellular Carcinoma", "Gastric Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "ADI-PEG 20 plus modified FOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2014-11", "completion_date": "2020-02", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-21T22:45:22.299Z", "location_count": 10, "location_summary": "San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02102022" } ] }